KPTI

Bearish

Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell

Karyopharm Therapeutics receives a reiterated Sell rating due to ongoing clinical and commercial challenges with its drug selinexor (Xpovio). Stagnant...

Seeking Alpha 3 days ago 0

Bullish

Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology

Karyopharm Therapeutics Inc. will present positive results from its Phase 3 SENTRY trial for selinexor plus ruxolitinib in myelofibrosis at the ASCO 2...

Karyopharm 2 weeks ago 0